Companies Looking Towards Future Revenue with New Diabetes Therapies
allpennystocks Newsletter
You can read the original version online:
http://ymlp259.net/zjJQOW ——————————————————————————– March 28, 2012 Special Report ….
Companies Looking Towards Future Revenue with New Diabetes Therapies For the full special report, CLICK HERE: (http://www.allpennystocks.com/aps_ca/special_reports/258/Companies-Looking-Towards-Future-Revenue-with-New-Diabetes-Therapies.htm).
Companies mentioned in this e-mail include:
* ALR Technologies, Inc. (OTCBB:ALRT).
* PositiveID Corp. (OTCBB:PSID).
* MannKind Corporation (Nasdaq:MNKD).
* Bristol-Meyers Squibb Co. (NYSE:BMY).
* AstraZeneca PLC (NYSE:AZN).
* Sirona Biochem Corp. (TSX-Venture:SBM).
ALLPENNYSTOCKS.COM NEWS ARTICLE Mar 28, 2012 (AllPennyStocks.com Media, Inc.) – Diabetes is reaching epidemic levels across the world, a disease that now affects more than 365 million people globally. The latest edition of the Diabetes Atlas from the International Diabetes Foundation (IDF) estimates that in addition to the 366 million diagnoses patients, as many as 183 million more people are unaware that they have the disease. The IDF said in their latest report that they expect the number of diagnosed diabetes patients to reach 552 million – or 10 percent of the global population – by the year 2030.
Currently, diabetes is the most expensive chronic disease in the world. According to its 2007 report, the American Diabetes Association estimated that the national cost of diabetes in the U.S. exceeds $174 billion annually.
With this in mind, countless companies in the biotechnology and medical device space are researching, developing and marketing products that can help lower the occurrence rate of diabetes and cut the massive associated expenses. A few, such as ALR Technologies, Inc.
(OTCBB:ALRT) and PositiveID Corp. (OTCBB:PSID) have received FDA 510(k) marketing clearance pursuant to their medical device technologies. Others are taking the biotech route and developing therapies to address core symptoms related to insulin in the body. On the whole, the list of current drugs that are used in treating patients with diabetes can be long and confusing with no one particular medication performing at levels to control the growth rate of the disease, thus leaving a large void of unmet medical need to be filled.
As far as up-and-coming drugs, California-based MannKind Corporation (Nasdaq:MNKD) is in late-stage development of AFREEZA®, a novel, fast-acting mealtime insulin therapy for the treatment of adults with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia.
MannKind has developed AFREEZA® as a combination drug/device consisting of the Company’s proprietary Technosphere® particles onto which insulin molecules are loaded. The particles are then aerosolized and inhaled deep into the lung using MannKind’s AFREEZA® inhaler. The Technosphere® Technology Platform was developed by MannKind as a potentially superior and easy to use drug delivery system that mimics the pharmacokinetics of intra-arterial administration. After rejections from the FDA in 2010 and again in 2011, MannKind is conducting Phase 3 clinical trials per guidance from the Food and Drug Administration as issued in a second complete response letter in from the FDA in January 2011 and End-of-Review meetings in May of 2011.
MannKind is also developing MKC253, a formulation of GLP-1 (glucagon-like peptide) on Technosphere® particles that is delivered using its inhaler. MKC253 is in Phase 1 clinical trials for the treatment of type 2 diabetes.
Also taking a lump recently from the FDA for potentially a new diabetes therapy to hit the market are partners Bristol-Meyers Squibb Co. (NYSE:BMY) and AstraZeneca PLC (NYSE:AZN). About two months ago, the FDA told the companies that it couldn’t approve their latest and greatest drug, dapagliflozin for Type 2 diabetes. The drug has received high praise as being a part of a new class of drugs for Type 2 diabetes called SGLT-2 (sodium glucose transporter) inhibitors, which reduce blood sugar by increasing how much is excreted in the urine and also helps patients lose weight.
Obesity has been proven to play a role as a major contributor in the occurrence rate of diabetes, so the control of weight in addition to blood sugar is heralded as holding a potential key to new, effective treatment at the core of diabetes. Type 2 diabetes is far and away the most prevalent type, accounting for more than 90 percent of all diabetes cases.
The U.S. regulators put a snag in BMY and AZN’s development of the once-a-day pill dapagliflozin by citing elevated rates of bladder and breast cancer seen in clinical studies, plus concerns about infections and possible liver damage. The FDA wants more data and if it requires more testing, it would likely delay any chance at NDA approval by at least two years.
The positive thing is that companies are making progress down the SGLT-2 inhibitors pathway. Research has shown that, in people with Type 2 diabetes, SGLT-2 inhibitors can be used to improve glycemic control, stabilize insulin requirements, and reduce weight without increasing major hypoglycemic (low blood sugar)episodes.
In early stages on the regulatory pathway of this new class of drugs for diabetes is Sirona Biochem Corp. (TSX-Venture:SBM) (Pink Sheets:SRBCF), a biotechnology company utilizing a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. The company has a pipeline that is being developed for diabetes therapeutics, cancer vaccine antigens, skin de-pigmenting and anti-aging agents for cosmetic use, and biological ingredients.
Sirona Biochem is breaking-down barriers related to carbohydrate-based molecules. Essential to life, carbohydrates, or sugar molecules, have the potential for ground-breaking pharmaceutical and cosmetic development, but have been limited in development because of the lack of stability generally exhibited by carbohydrate molecules. For example, when coming into contact with enzymes, carbohydrate-based molecules can easily break down or become toxic, making them difficult to produce as pharmaceutical products. Through award-winning technologies developed by Sirona’s French subsidiary, TFChem, the problem has been bridged;allowing the company to explore the vast uses for carbohydrate-based molecules like never done before.
Sirona’s recent pre-clinical data demonstrated the ability of its flagship compound, SBM-TFC-039, to control glycemic levels in Type 2 diabetes rat models. SMB-TFC-039 was been shown to be well tolerated while rapidly reducing the blood glucose level in obese diabetic rats.
In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats. Additionally, there was a strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
In addition to the SGLT inhibitor program, Sirona Biochem is simultaneously progressing its studies of skin lighteners and anti-aging agents for cosmetic use, inducers for recombinant protein production and adjuvants for cell and organ preservation that all leverage its chemistry technology. Information released just two weeks ago showed Sirona’s inducer SBM-TFC-358 produced more protein than IPTG, a leading commercially available inducer, and was able to maintain induction over a longer period. Inducers are carbohydrates which trigger recombinant protein production, which can be used in research and the manufacturing of insulin and other drugs. Common inducers today use carbohydrates, which as stated before, are far more difficult to work with because of their instability.
While still early in some research, Sirona has quickly established itself as a leader in specific biotechnology arenas with the ability for massive vertical and horizontal expansion. Trading at just over a dime per share and with a market cap of under $8 million, it is hard to look past the company’s offerings with some able to reach commercialization in short order. Proper due diligence on any of the companies mentioned is, as always, encouraged.
Click here for the rest of the report: (http://www.allpennystocks.com/aps_ca/special_reports/258/Companies-Looking-Towards-Future-Revenue-with-New-Diabetes-Therapies.htm) OVERVIEW Sirona Biochem Corp. is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules.
For more information on Sirona Biochem Corp., CLICK HERE:
(http://www.allpennystocks.com/aps_ca/company_spotlights/archives/sbm.asp)..
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web-based patient management platform for medical professionals to improve compliance and management of care plans of patients in their homes. HeC is currently programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases.
For more information on ALR Technologies, Inc., CLICK HERE:
( http://www.alrt.com ).
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America`s homeland defense industry. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
For more information on PositiveID Corp., CLICK HERE:
( http://www.PositiveIDCorp.com ).
MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
For more information on MannKind Corp., CLICK HERE:
( http://www.mannkindcorp.com ).
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
For more information on Bristol-Myers Squibb, CLICK HERE:
( http://www.bms.com ).
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information on AstraZeneca, CLICK HERE:
( http://www.astrazeneca-us.com ).
Forward Looking Statements This report includes forward-looking statements that reflect the mentioned companies current expectations about its future results, performance, prospects and opportunities. the mentioned companies has tried to identify these forward-looking statements by using words and phrases such as “may,” “will,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plan,” “should,” “typical,” “preliminary,” “we are confident” or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause the mentioned companies actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company`s growth expectations and ongoing funding requirements, and specifically, the Company`s growth prospects with scalable customers, and those outlined above. Other risks include the Company`s limited operating history, the Company`s history of operating losses, consumers` acceptance, the Company`s use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company`s securities, the possible volatility of the Company`s stock price, the concentration of ownership, and the potential fluctuation in the Company`s operating results.
Disclaimer AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable.
For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company`s expectations and estimates.
This is an advertisement for the mentioned companies The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
© 1999-2012 AllPennyStocks.com. All rights reserved.
AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views; opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in it`s disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site. AllPennyStocks.com has been compensated seven thousand five hundred dollars by a third-party, Pristine Capital Corp. for its efforts in presenting the V.SBM profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold. Information presented on our web site and within our reports contain “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov ( http://www.sec.gov ) and/or the National Association of Securities Dealers (NASD) at:
http://www.nasd.com ( http://www.nasd.com ). Readers can review all public filings by companies at the SEC`s EDGAR page. The NASD has published information on how to invest carefully at its web site.
_____________________________ Change email address / Leave mailing list: http://ymlp259.net/ugjheqmgsgeyyqygujmeggmqbybw Powered by YourMailingListProvider